Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
Get the latest multiple sclerosis news, patient views, and caregiver perspectives from one of the largest MS communities online.
Top 10 MS stories of 2023 - Multiple Sclerosis News Today
Jan 2, 2024 · Throughout 2023, Multiple Sclerosis News Today brought consistent coverage to our readers of the latest scientific research, developments in treatment, and clinical trials for multiple sclerosis (MS).
1-year fenebrutinib inhibits nearly all MS signs in relapsing MS trial
Sep 6, 2024 · News; 1-year fenebrutinib curbs nearly all disease activity in relapsing MS trial ... to present the data in more detail at the upcoming Congress of the European Committee for Treatment and ...
ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
Sep 23, 2024 · The findings were presented in a pair of Sanofi-sponsored late-breaking presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, which was ...
ACTRIMS 2024 - Multiple Sclerosis News Today
Multiple Sclerosis News Today is providing coverage of the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 Feb. 29-March 2 in West Palm Beach ...
ACTRIMS 2024: 2 treatments to aid remyelination in MS nearing...
Mar 6, 2024 · Lang discussed the development of the new treatment candidates at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, which was held last week virtually ...
AAN 2024: In MS study, long-term CNM-Au8 shows myelin, nerve …
Apr 18, 2024 · Note: The Multiple Sclerosis News Today team is providing coverage of the American Academy of Neurology (AAN) 2024 Annual Meeting April 13-18. Go here to see the latest stories from the conference.
About Us - Multiple Sclerosis News Today
Multiple Sclerosis News Today is a digital platform intended to provide the multiple sclerosis (MS) community with the most recent news and information on MS, as well as first-hand community ...
FDA grants tolebrutinib breakthrough therapy designation in SPMS
Dec 17, 2024 · In addition to HERCULES, Sanofi’s clinical development program for tolebrutinib included three other Phase 3 trials: the identical GEMINI 1 (NCT04410978) and GEMINI 2 (NCT04410991) studies ...
Stable MS patients free of disease activity after DMT stops: Study
Dec 18, 2024 · Nearly all participants (89.9%) had relapsing-remitting MS, while the remaining had secondary progressive MS.Most were women (67.4%), with a median age of 54, and the median time since the last ...